Is LLY a good stock to buy right now?

Based on our 6-factor quantitative model, ELI LILLY & Co (LLY) receives a "Hold" rating with a composite score of 46.1/100. It is ranked #1,418 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 52/100, Momentum 50/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for LLY?

ELI LILLY & Co (LLY) has a "Hold" rating and 3-star score. The composite score of 46.1 ranks it #1,418 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is LLY in?

ELI LILLY & Co operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $852.73 billion. It is classified as a mega-cap stock.

Does LLY pay a dividend?

Yes, LLY pays a dividend with a current yield of 0.76%. For every $1,000 invested, you would receive approximately $7.60 in annual dividend income.

What is LLY's P/E ratio?

LLY has a trailing P/E ratio of 55.55x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is LLY?

LLY's quality factor score is 50/100. Gross margin: 82.7%. ROE: 56.4% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is LLY valued compared to peers?

LLY's value factor score is 52/100 (higher = cheaper). Key multiples: P/E 55.5x, EV/EBITDA 43.7x. Valuation is roughly in line with peers.

What is LLY's debt level?

LLY's debt-to-equity ratio is 324%. Sector average: 32%. Elevated leverage increases credit risk.

LLY has a beta of 0.68, meaning it is less volatile than the market. Stability score: 64/100.

Does LLY have high short interest?

LLY's short interest factor score is 23/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

LLY Stock Analysis: Hold (Score 46.1/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
LLY	-1.65%	+0.42%	-6.18%	-12.58%	+30.32%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.58%	-3.19%	-6.52%	-12.22%	+0.79%	-	-	-
Alpha vs Sector	-0.29%	+0.08%	-2.37%	-7.74%	+21.11%	-	-	-

Metric	LLY	Benchmark
P/E Ratio	55.5x	+135%
EV/EBITDA	43.7x	+589%
Price / Book	31.4x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
LLY ELI LILLY & Co	46	50	52	50	55.6x	56.4%	82.7%	24.6%	55.7%	324.0x	$852.7B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.8%	0.8%	0.8%	0.8%	0.8%	0.7%	0.8%	0.8%	0.8%	0.8%	0.7%
Operating Margin %	0.3%	0.4%	0.3%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.1%	0.2%
EBITDA Margin %	0.3%	0.4%	0.3%	0.2%	0.2%	0.2%	0.3%	0.3%	0.2%	0.2%	0.2%
Net Margin %	0.2%	0.3%	0.2%	0.2%	0.2%	0.2%	0.3%	0.4%	0.2%	-0.0%	0.1%
FCF Margin %	-16.1%	-	-	-	-	-	20.8%	17.0%	17.6%	22.7%	18.0%
ROE %	0.6%	0.8%	0.7%	0.5%	0.6%	0.6%	1.1%	3.2%	0.3%	-0.0%	0.2%
ROA %	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.1%	-0.0%	0.1%
ROIC %	25.4%	76.6%	22.9%	17.3%	21.0%	18.8%	25.8%	25.2%	23.0%	8.5%	13.8%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.8%

0.7%

0.8%

0.7%

Operating Margin %

0.3%

0.4%

0.3%

0.2%

0.1%

0.2%

EBITDA Margin %

0.3%

0.4%

0.3%

0.2%

0.3%

0.2%

Net Margin %

0.2%

0.3%

0.2%

0.3%

0.4%

0.2%

-0.0%

0.1%

FCF Margin %

-16.1%

20.8%

17.0%

17.6%

22.7%

18.0%

ROE %

0.6%

0.8%

0.7%

0.5%

0.6%

1.1%

3.2%

0.3%

-0.0%

0.2%

ROA %

0.1%

0.2%

0.1%

0.2%

0.1%

-0.0%

0.1%

ROIC %

25.4%

76.6%

22.9%

17.3%

21.0%

18.8%

25.8%

25.2%

23.0%

8.5%

13.8%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$57.3B	$65.2B	$45.0B	$34.1B	$28.5B	$28.3B	$24.5B	$22.3B	$24.6B	$20.0B	$21.2B	$20.0B
	—	$11.1B	$8.4B	$7.1B	$6.6B	$7.3B	—	—	—	—	—	—
	$47.5B	$54.1B	$36.6B	$27.0B	$21.9B	$21.0B	$19.1B	$17.6B	$18.1B	$15.5B	$15.6B	$14.9B
Gross Margin	82.7%	83.0%	81.3%	79.3%	76.8%	74.2%	77.7%	78.8%	78.2%	77.7%	73.1%	74.8%
	—	$11.1B	$8.6B	$7.4B	$6.4B	$6.4B	—	—	—	—	—	—
Research & Development	—	—	—	—	$7.2B	$7.0B	$6.7B	$5.8B	$7.3B	$6.2B	$5.3B	$5.3B
Depreciation	—	—	—	—	—	—	$1.3B	$1.2B	$1.6B	$1.6B	$1.5B	$1.4B
Total Operating Expenses	—	$28.4B	$23.9B	$20.5B	$15.1B	$14.9B	—	—	—	—	—	—
	$19.1B	$25.7B	$12.7B	$6.6B	$6.8B	$6.2B	$6.1B	$5.0B	$3.7B	$2.0B	$3.5B	$2.7B
EBIT	$19.1B	$25.7B	$12.7B	$6.6B	$6.8B	$6.2B	$6.1B	$5.0B	$3.7B	$2.0B	$3.5B	$2.7B
EBITDA	$19.1B	$25.7B	$12.7B	$6.6B	$6.8B	$6.2B	$8.6B	$6.5B	$5.3B	$3.9B	$4.9B	$4.2B
Operating Margin	31.4%	39.5%	28.1%	19.2%	23.8%	21.7%	24.7%	22.3%	16.4%	10.0%	15.4%	13.5%
EBITDA Margin	33.2%	39.5%	28.2%	19.2%	23.8%	21.7%	34.9%	29.1%	21.5%	19.4%	23.0%	21.1%
	—	—	—	$486M	$332M	$340M	—	—	—	—	—	—
	—	$25.7B	$12.7B	$6.6B	$6.8B	$6.2B	—	—	—	—	—	—
Income Tax Expense	—	$5.1B	$2.1B	$1.3B	$562M	$574M	$1.0B	$628M	$564M	$2.4B	$636M	$382M
	$15.0B	$20.6B	$10.6B	$5.2B	$6.2B	$5.6B	$6.2B	$8.3B	$3.2B	-$204M	$2.7B	$2.4B
Net Margin	24.6%	31.7%	23.5%	15.4%	21.9%	19.7%	25.2%	37.3%	15.0%	-1.0%	12.9%	12.1%
	$23.00	$23.00	$11.76	$5.82	$6.93	$6.15	$6.82	$8.93	$3.14	$-0.19	$2.59	$2.27
Diluted EPS	$23.00	$22.95	$11.71	$5.80	$6.90	$6.12	$6.82	$8.93	$3.14	$-0.19	$2.59	$2.27
Weighted Avg Basic	—	897M	901M	900M	902M	907M	—	—	—	—	—	—
Weighted Avg Diluted	—	899M	904M	903M	905M	912M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$57.3B

$65.2B

$45.0B

$34.1B

$28.5B

$28.3B

$24.5B

$22.3B

$24.6B

$20.0B

$21.2B

$20.0B

—

$11.1B

$8.4B

$7.1B

$6.6B

$7.3B

—

$47.5B

$54.1B

$36.6B

$27.0B

$21.9B

$21.0B

$19.1B

$17.6B

$18.1B

$15.5B

$15.6B

$14.9B

Gross Margin

82.7%

83.0%

81.3%

79.3%

76.8%

74.2%

77.7%

78.8%

78.2%

77.7%

73.1%

74.8%

—

$11.1B

$8.6B

$7.4B

$6.4B

—

Research & Development

—

$7.2B

$7.0B

$6.7B

$5.8B

$7.3B

$6.2B

$5.3B

Depreciation

—

$1.3B

$1.2B

$1.6B

$1.5B

$1.4B

Total Operating Expenses

—

$28.4B

$23.9B

$20.5B

$15.1B

$14.9B

—

$19.1B

$25.7B

$12.7B

$6.6B

$6.8B

$6.2B

$6.1B

$5.0B

$3.7B

$2.0B

$3.5B

$2.7B

EBIT

$19.1B

$25.7B

$12.7B

$6.6B

$6.8B

$6.2B

$6.1B

$5.0B

$3.7B

$2.0B

$3.5B

$2.7B

EBITDA

$19.1B

$25.7B

$12.7B

$6.6B

$6.8B

$6.2B

$8.6B

$6.5B

$5.3B

$3.9B

$4.9B

$4.2B

Operating Margin

31.4%

39.5%

28.1%

19.2%

23.8%

21.7%

24.7%

22.3%

16.4%

10.0%

15.4%

13.5%

EBITDA Margin

33.2%

39.5%

28.2%

19.2%

23.8%

21.7%

34.9%

29.1%

21.5%

19.4%

23.0%

21.1%

—

$486M

$332M

$340M

—

$25.7B

$12.7B

$6.6B

$6.8B

$6.2B

—

Income Tax Expense

—

$5.1B

$2.1B

$1.3B

$562M

$574M

$1.0B

$628M

$564M

$2.4B

$636M

$382M

$15.0B

$20.6B

$10.6B

$5.2B

$6.2B

$5.6B

$6.2B

$8.3B

$3.2B

-$204M

$2.7B

$2.4B

Net Margin

24.6%

31.7%

23.5%

15.4%

21.9%

19.7%

25.2%

37.3%

15.0%

-1.0%

12.9%

12.1%

$23.00

$11.76

$5.82

$6.93

$6.15

$6.82

$8.93

$3.14

$-0.19

$2.59

$2.27

Diluted EPS

$23.00

$22.95

$11.71

$5.80

$6.90

$6.12

$6.82

$8.93

$3.14

$-0.19

$2.59

$2.27

Weighted Avg Basic

—

897M

901M

900M

902M

907M

—

Weighted Avg Diluted

—

899M

904M

903M

905M

912M

—

ELI LILLY & Co (LLY) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does ELI LILLY & Co Do?

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY & Co (LLY) is classified as a mega-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO David A. Ricks and employs approximately 39,000 people, headquartered in Indianapolis, Indiana. With a market capitalization of $852.7B, LLY is one of the largest companies in the Healthcare sector.

ELI LILLY & Co (LLY) Stock Rating — Hold (April 2026)

As of April 2026, ELI LILLY & Co receives a Hold rating with a composite score of 46.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.LLY ranks #1,418 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ELI LILLY & Co ranks #117 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LLY Stock Price and 52-Week Range

ELI LILLY & Co (LLY) currently trades at $940.06. The stock lost $15.13 (1.6%) in the most recent trading session. The 52-week high for LLY is $1133.95, which means the stock is currently trading -17.1% from its annual peak. The 52-week low is $623.78, putting the stock 50.7% above its annual trough. Recent trading volume was 2.0M shares, reflecting moderate market activity.

Is LLY Overvalued or Undervalued? — Valuation Analysis

ELI LILLY & Co (LLY) carries a value factor score of 52/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 55.55x, compared to the Healthcare sector average of 23.63x — a premium of 135%. The price-to-book ratio stands at 31.35x, versus the sector average of 2.75x. The price-to-sales ratio is 14.51x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, LLY trades at 43.66x EV/EBITDA, versus 6.34x for the sector.

Overall, LLY's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

ELI LILLY & Co Profitability — ROE, Margins, and Quality Score

ELI LILLY & Co (LLY) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 56.4%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 13.3% versus the sector average of -33.1%.

On a margin basis, ELI LILLY & Co reports gross margins of 82.7%, compared to 71.5% for the sector. The operating margin is 31.4% (sector: -66.1%). Net profit margin stands at 24.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 55.7% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

LLY Debt, Balance Sheet, and Financial Health

ELI LILLY & Co has a debt-to-equity ratio of 324.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.58x, suggesting adequate working capital coverage. Total debt on the balance sheet is $42.51B. Cash and equivalents stand at $9.79B.

LLY has a beta of 0.68, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ELI LILLY & Co is 64/100, reflecting average volatility within the normal range for its sector.

ELI LILLY & Co Revenue and Earnings History — Quarterly Trend

In TTM 2026, ELI LILLY & Co reported revenue of $57.33B and earnings per share (EPS) of $23.00. Net income for the quarter was $14.97B. Gross margin was 82.7%. Operating income came in at $19.05B.

In FY 2025, ELI LILLY & Co reported revenue of $65.18B and earnings per share (EPS) of $23.00. Net income for the quarter was $20.64B. Gross margin was 83.0%. Revenue grew 44.7% year-over-year compared to FY 2024. Operating income came in at $25.73B.

In Q3 2025, ELI LILLY & Co reported revenue of $17.60B and earnings per share (EPS) of $6.22. Net income for the quarter was $5.58B. Gross margin was 82.9%. Revenue grew 53.9% year-over-year compared to Q3 2024. Operating income came in at $7.23B.

In Q2 2025, ELI LILLY & Co reported revenue of $15.56B and earnings per share (EPS) of $6.30. Net income for the quarter was $5.66B. Gross margin was 84.3%. Revenue grew 37.6% year-over-year compared to Q2 2024. Operating income came in at $6.78B.

Over the past 8 quarters, ELI LILLY & Co has demonstrated a growth trajectory, with revenue expanding from $11.30B to $57.33B. Investors analyzing LLY stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LLY Dividend Yield and Income Analysis

ELI LILLY & Co (LLY) currently pays a dividend yield of 0.8%. At this yield, a $10,000 investment in LLY stock would generate approximately $$76.00 in annual dividend income. With a net margin of 24.6%, the dividend appears well-covered by earnings, suggesting sustainable payouts going forward.

LLY Momentum and Technical Analysis Profile

ELI LILLY & Co (LLY) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 23/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

LLY vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ELI LILLY & Co (LLY) ranks #117 out of 838 stocks based on the Blank Capital composite score. This places LLY in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LLY against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LLY vs S&P 500 (SPY) comparison to assess how ELI LILLY & Co stacks up against the broader market across all factor dimensions.

LLY Next Earnings Date

No upcoming earnings date has been announced for ELI LILLY & Co (LLY) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LLY? — Investment Thesis Summary

ELI LILLY & Co presents a balanced picture with arguments on both sides. Low volatility (stability score 64/100) reduces downside risk.

In summary, ELI LILLY & Co (LLY) earns a Hold rating with a composite score of 46.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LLY stock.

Related Resources for LLY Investors

Explore more research and tools: LLY vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LLY head-to-head with peers: LLY vs AZN, LLY vs SLGL, LLY vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Here's Why Buying This Vanguard Index Fund Today Could Be the Best Financial Decision You Ever Make

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships

India GLP 1 Generics Test Novo Nordisk Pricing Power And Valuation

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

ELI LILLY & Co (LLY) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does ELI LILLY & Co Do?

ELI LILLY & Co (LLY) Stock Rating — Hold (April 2026)

LLY Stock Price and 52-Week Range

Is LLY Overvalued or Undervalued? — Valuation Analysis

ELI LILLY & Co Profitability — ROE, Margins, and Quality Score

LLY Debt, Balance Sheet, and Financial Health

ELI LILLY & Co Revenue and Earnings History — Quarterly Trend

LLY Dividend Yield and Income Analysis

LLY Momentum and Technical Analysis Profile

LLY vs Competitors — Healthcare Sector Ranking and Peer Comparison

LLY Next Earnings Date

Should You Buy LLY? — Investment Thesis Summary

Related Resources for LLY Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Here's Why Buying This Vanguard Index Fund Today Could Be the Best Financial Decision You Ever Make

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

LLY Launches GLP-1 Pill, Expands Access Through Pharmacy Partnerships

India GLP 1 Generics Test Novo Nordisk Pricing Power And Valuation